Please use this identifier to cite or link to this item: https://doi.org/10.1158/1078-0432.CCR-09-2341
Title: Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms
Authors: Ogawa, S.
Shih, L.-Y.
Suzuki, T.
Otsu, M.
Nakauchi, H.
Koeffler, H.P. 
Sanada, M.
Issue Date: 1-Aug-2010
Citation: Ogawa, S., Shih, L.-Y., Suzuki, T., Otsu, M., Nakauchi, H., Koeffler, H.P., Sanada, M. (2010-08-01). Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clinical Cancer Research 16 (15) : 3825-3831. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-09-2341
Abstract: c-CBL encodes a 120-kDa protein involved in intracellular signal transduction in a wide variety of cell types. Recently, frequent mutations of c-CBL have been reported in myeloid neoplasms showing both myelodysplastic and myeloproliferative features, in which most mutations are present in a homozygous state, as a result of allelic conversion in 11q. c-CBL has ubiquitin E3 ligase activity for a wide variety of tyrosine kinases, and thereby, negatively regulates tyrosine kinase signaling. Accordingly, c-CBL seems to have tumor suppressor functions, loss of which promotes tumorigenesis. On the other hand, once mutated, it is converted to an oncogenic protein and commits to myeloid leukemogenesis through a kind of gain of function causing aberrant signal transduction. The inhibition of mutant CBL protein or signaling pathways that it activates would have a role in therapeutics of myeloid neoplasms with CBL mutations. ©2010 AACR.
Source Title: Clinical Cancer Research
URI: http://scholarbank.nus.edu.sg/handle/10635/126921
ISSN: 10780432
DOI: 10.1158/1078-0432.CCR-09-2341
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

28
checked on Oct 20, 2021

WEB OF SCIENCETM
Citations

23
checked on Oct 20, 2021

Page view(s)

82
checked on Oct 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.